JSPR Clinical trials Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria Published June 14, 2025 at 02:00 PM 11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response Find similar articles on Candlesense globenewswire